Molecular determinants for interaction of SHEP1 with Cas localize to a highly solvent-protected region in the complex  by Derunes, Céline et al.
FEBS Letters 580 (2006) 175–178Molecular determinants for interaction of SHEP1 with Cas localize
to a highly solvent-protected region in the complex
Ce´line Derunesa,1, Rosemary Burgessa, Emilio Irahetaa, Robert Kellerera, Kathleen Becherera,
Chris R. Gessnerb, Sheng Lib, Krissi Hewittb, Kristiina Vuoria, Elena B. Pasqualea,*,
Virgil L. Woods Jr.b,*, Kathryn R. Elya,*
a Cancer Center, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
b Department of Medicine and Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA
Received 10 October 2005; revised 8 November 2005; accepted 28 November 2005
Available online 12 December 2005
Edited by Christian GriesingerAbstract Protein–protein interactions between SHEP and Cas
proteins inﬂuence cellular signaling through tyrosine kinases, as
well as integrin-mediated signaling, and may be linked to anties-
trogen resistance. Data from past studies suggests that associa-
tion between SHEP and Cas proteins is critical for these cellular
eﬀects. In this study, the interacting domains of each protein
were co-expressed in bacteria and a soluble stable complex was
puriﬁed. Deuterium exchange mass spectrometry was used to de-
ﬁne regions that are buried when SHEP1 is in complex with Cas.
The results reveal four segments in SHEP1 that are highly pro-
tected, including a region (residues 619–640) that contains a key
residue, tyrosine 635, required for association with Cas. This re-
gion is predominately hydrophilic, yet remains protected from
solvent in the complex.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: SHEP1; p130Cas; Cell signaling; Deuterium
exchange; Mass spectrometry; Cell signaling1. Introduction
The use of antiestrogens, particularly tamoxifen, is an eﬀec-
tive treatment for hormone-responsive breast cancer that re-
duces tumor recurrence and increases survival of patients
with estrogen receptor-positive breast cancer. Resistance to
antiestrogens, however, is a serious obstacle in the manage-
ment of breast cancer. The scaﬀolding protein BCAR1 (breast
cancer antiestrogen resistance 1), also known as Cas, is one of
the proteins associated with anti-estrogen resistance [1,2]. Cas
is also a key molecule in intracellular signaling pathways that
promote cell proliferation, migration and invasion [3].
The gene product at another locus, BCAR3 (also known as
AND-34 or SHEP2), also promotes antiestrogen resistance [4]
and interacts with Cas [5]. SHEP proteins contain a guanine
nucleotide exchange factor (GEF) domain that mediates bind-
ing to Ras family GTPases but lacks enzymatic activity [6–8].*Corresponding authors.
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doi:10.1016/j.febslet.2005.11.070Interestingly, the GEF domain of SHEP proteins is also re-
quired for Cas binding [9,10].
Increasing evidence suggests that SHEP and Cas proteins
share signaling functions that aﬀect cell proliferation and
motility [8,11,12], and these functional roles may be linked
to antiestrogen resistance. The physical interaction between
SHEP and Cas proteins is key to this activity. We previously
identiﬁed a critical tyrosine in the Cas association domain of
SHEP1 that marks a selective site for SHEP1–Cas interaction
[8]. Mutation of this tyrosine (Tyr635) to glutamic acid dis-
rupts the ability of SHEP1 to bind to Cas. Moreover, this
mutation blocks SHEP1 from promoting Cas–Crk association
and cell migration in response to epidermal growth factor, sug-
gesting that these functional activities of SHEP1 depend on
formation of a SHEP1–Cas complex.
To further investigate the molecular determinants of the
interaction between SHEP1 and Cas, in the present study
we used enhanced peptide amide deuterium exchange mass
spectrometry (DXMS) to identify regions in SHEP1 that are
highly protected from deuterium exchange when SHEP1 is
in complex with Cas. The data indicate that the functionally
important Tyr635 is found in a region of the molecule that
is protected from aqueous solvent in the complex. These re-
sults also have broader implications to understand molecular
contacts that mediate protein–protein interactions in cellular
signaling.2. Materials and methods
2.1. Co-expression system
The cDNA sequence encoding the C-terminus of SHEP1 (residues
362–702) was cloned into the pEGST expression vector, to express
the Cas association domain of SHEP1 as a glutathione-S-transferase
(GST) fusion protein, with a thrombin cleavage site between the
GST partner and SHEP1. The cDNA encoding the C-terminus of
Cas (residues 836–968) was cloned into the pAC28 expression vector
to express this region of Cas with an N-terminal hexa-histidine tag
in the same bacteria expressing GST–SHEP1 [13].
2.2. Protein expression and puriﬁcation
To produce the complex, plasmids encoding GST–SHEP1 and His6–
Cas were transformed into Escherichia coli BL21(DE3) (Stratagene). A
300 ml overnight culture was diluted into 3 L of LB medium contain-
ing 100 lg/ml ampicillin plus 50 lg/ml kanamycin and grown with
shaking at 37 C to a cell density of A600 = 0.6. The temperature wasation of European Biochemical Societies.
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the addition of 1.5 mM isopropyl-1-thio-b-D-galactopyranoside. After
5–6 h, cells were collected by centrifugation at 8000 rpm, and stored
overnight at 80 C.
For puriﬁcation of the complex, frozen cells were thawed, re-sus-
pended in 10 ml of extraction solution #1 (50 mM Tris, pH 8, 5 mM
EDTA, 14 mM b-mercaptoethanol, 0.005% NaN3, 0.04 mg/ml lyso-
zyme, 1 mM phenylmethylsulfonyl ﬂuoride or PMSF) per g of cells
and disrupted by douncing. After 15 min, 1 ml of 10· extraction solu-
tion #2 (1.5 M NaCl, 100 mM CaCl2, 100 mM MgSO4, 20 lg/ml
DNase, 50 lg/ml trypsin inhibitor) was added per 10 ml of cell suspen-
sion. After mixing for 15 min at 4 C, the lysate was cleared of cell deb-
ris by centrifugation at 18000 rpm. The SHEP1–Cas complex was
isolated from the lysate ﬁrst by aﬃnity chromatography using glutathi-
one–agarose (GA) resin (Sigma), equilibrated with GAM buﬀer
(50 mM Tris, pH 8.0, 100 mM NaCl, 5 mM b-mercaptoethanol). The
loaded column was washed overnight with GAM buﬀer and the com-
plex was eluted by disrupting binding of the GST-fusion protein using
10 mM reduced glutathione freshly added to GAM buﬀer. After dial-
ysis versus GAM buﬀer containing 20 mM imidazole, a second aﬃnity
chromatography was performed using a Ni2+–NTA superﬂow resin
(Qiagen) equilibrated with the dialysis buﬀer. The loaded resin was
washed with the dialysis buﬀer and the complex was eluted with
GAM buﬀer containing 150 mM imidazole by release of the His6-
tagged partner. After dialysis versus HEPES buﬀer (20 mM HEPES,
pH 6.5, 100 mM NaCl and 5 mM b-mercaptoethanol), the GST part-
ner was removed by thrombin cleavage using 7 U of human thrombin
(Sigma Chemical Corp.) per mg of fusion protein. After 5 h at room
temperature, the digestion was terminated by the addition of 1 mM
AEBSF. The SHEP1–Cas complex was separated from cleaved GST
and residual thrombin by a chromatographic step using tandem p-
aminobenzamidine (Sigma Chemical Corp.)/GA columns. Puriﬁed
complex was stored at 4 C in HEPES buﬀer containing 1 mM PMSF.
2.3. Protein fragmentation maps for DXMS
Peptide probe maps were prepared as previously described [14–19].
Brieﬂy, protein complex solution (10 mg/ml) was diluted threefold with
storage buﬀer and maintained at 0 C on melting ice. Stock exchange
quench buﬀer was added to each sample to a ﬁnal concentration of
0.5% formic acid, 0.05–4 M Gdn Æ HCl, 10% glycerol, ﬂash frozen,
and stored at 80 C. On-line proteolysis was performed with a so-
lid-phase porcine pepsin column (Sigma Chemical Co.) coupled to
20AL support material (PerSeptive Biosystems), followed by digestion
on an Aspergillus saitoi fungal protease column (Type XIII EC
3.4.23.6, Sigma Chemical Co.). Peptide fragments were resolved with
a C18 RP-HPLC column (Vydac Inc., Hesperia, CA), using a linear
acetonitrile gradient (5–45%) and analyzed on a Thermo Finnigan
LCQ electrospray mass spectrometer.Fig. 1. Functional domains in SHEP1 and Cas proteins. In this schematic rep
are shown. Domains are indicated by boxes within the linear sequence of each
complex are indicated by an arrow. In Cas, the domains are: SH3, SH3 dom
region; SBD, Src-binding domain; C-T, carboxyl-terminal domain (see [22,2
serine-rich domain; GEF, GEF domain. A key residue (Tyr635) for associatFor each digestion condition used, data were acquired by parallel
MS1 acquisition (Q-tof) and data-dependent MS2 acquisition (LCQ)
with dynamic exclusion. The SEQUEST software program (Thermo
Finnigan, San Jose, CA) identiﬁed the likely sequence of the parent
peptide ions. Tentative identiﬁcations were tested with specialized
DXMS data-reduction software (Sierra Analytics; [15,17,19]).
2.4. Deuteration of proteins and DXMS analysis
After establishing fragmentation maps for each protein in the com-
plex, amide hydrogen exchange-deuterated samples of the complex
were prepared and processed exactly as above, except that the protein
stock solution was diluted with deuterium oxide (D2O) containing
5 mM Tris Æ HCl, pD (uncorrected reading) 7.0, 150 mM NaCl, and
incubated for 10, 100, or 10000 s at 0 C on melting ice before quench-
ing with 4 M Gdn Æ HCl. Control samples of non-deuterated and equi-
librium-deuterated protein were processed identically. Data reduction
was performed with the DXMS software and corrected for back-ex-
change as reported previously [17,18,20].3. Results and discussion
Protein–protein interactions between SHEP and Cas pro-
teins and formation of a functional complex have important
implications for cellular signaling through tyrosine kinases as
well as integrin-mediated signaling, and the molecular mecha-
nism by which this complex induces antiestrogen resistance is
likely found within this milieu. Data from our past studies sug-
gest that a stable association between SHEP and Cas proteins
is critical for the cellular eﬀects. Thus, understanding the mode
of association between these two molecules is essential to de-
ﬁne the regulation eﬀected by the complex. To characterize
the physical interactions between SHEP1 and the docking pro-
tein Cas, protein fragments containing the interacting regions
in the two proteins were expressed in bacteria and puriﬁed
for biochemical analysis. The interacting domains reside with-
in the 133 carboxyl-terminal residues of Cas and the 341 car-
boxyl-terminal residues of SHEP1, as shown in Fig. 1. In
earlier experiments we produced a series of constructs encod-
ing segments of diﬀering lengths encompassing the interacting
regions of SHEP1 or Cas. The products were expressed indi-
vidually in bacteria as GST-fusion or hexa-histidine-tagged fu-
sion proteins. Although the proteins were soluble after aﬃnityresentation, the organization of functional domains in SHEP1 and Cas
protein, and the domains that associate when these two proteins form a
ain; PRR, proline-rich region; SD, substrate domain; SRR, serine-rich
3]) and for SHEP1 the domains are: SH2, SH2 domain; P/S, proline-
ion of these proteins is labeled.
Fig. 2. SDS–PAGE analysis of the puriﬁcation of the SHEP1/Cas
complex. The GST–SHEP1 and His6–Cas proteins were co-expressed
in the bacterial culture and puriﬁed by a two-step aﬃnity puriﬁcation.
First, aﬃnity puriﬁcation using GA resin separated the complex from
contaminants based on aﬃnity interaction of GST–SHEP1 with the
GA beads and the stable complex was eluted with reduced glutathione
(lane 2). Next, the stable complex was puriﬁed on Ni2+–NTA resin by
aﬃnity interactions of His6-tagged Cas, and eluted with imidazole
(lane 3). After concentration (lane 4), the aﬃnity tags were removed
from each protein in the complex by thrombin digestion (see text) and
the stable complex (lane 5) was used for DXMS experiments. (Note
that the small size of the Cas partner results in reduced intensity of the
band by Coomassie blue staining).
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over time (data not shown). Therefore, we turned to a new
strategy to co-express the optimal domains identiﬁed in preli-
minary screens of the fragments.
3.1. Puriﬁcation of the complex
The complex of GST–SHEP1 and His6–Cas was puriﬁed by
a two-step aﬃnity-binding protocol, taking advantage of the
fact that the two partners in the complex were expressed as fu-
sion proteins with diﬀerent tags, as described in Section 2. As
shown in Fig. 2, the complex was soluble and stable after these
two aﬃnity puriﬁcations and the dual aﬃnity puriﬁcation pro-
tocol ensured that only molecules that were in complex were
recovered after the second elution. The stability of the complex
was conﬁrmed by molecular sizing using gel ﬁltration (data not
shown).
After puriﬁcation of the complex, thrombin digestion was
used to remove the GST-fusion partner from SHEP1, by cleav-
age at a thrombin recognition site that had been inserted
between GST and SHEP1. Interestingly, thrombin also remo-
ved the hexa-histidine tag from Cas, although a thrombin site
had not been engineered in this construct. Typical yields of
10 mg/ml soluble complex were produced for biochemical
studies by this protocol.
3.2. Deuterium exchange and mass spectrometry
Enhanced peptide amide hydrogen–deuterium exchange
mass spectrometry (DXMS) was used to identify ﬂexible/disor-
dered regions in the two proteins in the SHEP1–Cas complex
and also to evaluate which regions in the two proteins are pro-
tected from deuterium exchange in the complex. The data ob-
tained can be correlated with structural analyses of each
partner to predict the contact sites that promote intermolecu-
lar interactions. The results are presented here for the SHEP1
partner, and the exchange data for the Cas fragment will be
published elsewhere. Preliminary studies established peptideFig. 3. Amide hydrogen exchange for the SHEP1 protein measured in the SH
for the experiments are shown above the top line. A color-coded grid indicates
the SHEP1–Cas complex at three incubation time points: 10, 100 and 1000
presents a more detailed representation of the highly solvent-protected sequ
peptide probe coverage are indicated by open rectangles. Direct comparison
protected from deuterium exchange even for prolonged periods.fragmentation maps for each of the partners in the complex,
with 246 of 340 residues (72%) of the sequence of the SHEP1
construct covered by high yield probe peptides (see Supple-
mental Materials). With these conditions, deuterium exchange
was performed on the complex using a range of deuteration
times (10–10000 s). The results of the deuterium exchange
for SHEP1 are shown in Fig. 3.
In SHEP1, four regions are highly solvent-protected in the
complex: 419–428, 460–488, 528–536, 619–640. The latter re-
gion, containing Tyr635, was of particular interest since we
had previously shown that this residue is required for associa-EP1/Cas complex. The sequence numbers of the SHEP1 fragment used
the % deuteration level for each individual SHEP1 peptide analyzed in
0 s. In Panel A, the entire SHEP1 sequence is shown, while Panel B
ence (residues 619–640) containing the key Tyr635 (boxed). Gaps in
of the exchange at the three time points reveals regions that remain
178 C. Derunes et al. / FEBS Letters 580 (2006) 175–178tion with Cas [8]. When this tyrosine was mutated to glutamic
acid, binding to Cas was disrupted, but when phenylalanine
was substituted at this position, binding to the Cas partner
was retained [8]. These results suggest that the SHEP1 interac-
tion with Cas is mediated by a hydrophobic contact at residue
635, which is maintained when phenylalanine is inserted but is
disrupted when the tyrosine is exchanged for a polar charged
residue such as glutamic acid. Since the negatively charged car-
boxylate side chain of glutamic acid could mimic a phosphate
group, the results of the pull down assays [8] may also suggest
that phosphorylation of Tyr635 inhibits formation of the
SHEP1–Cas complex. Interestingly, within the segment that
is most highly protected from deuterium exchange (residues
619–640), and may lie at the protein–protein interface, the se-
quence is predominately hydrophilic or polar except for the
leucine–tyrosine pair at residues 634–635.
This segment also deﬁnes a region of the C-terminal GEF
domain of SHEP1 that is critical for Cas binding but not bind-
ing to GTPases, since neither of the substitutions at residues
635 (glutamic acid or phenylalanine) blocks binding to R-
Ras [8]. Using homology alignment to compare the GEF do-
mains of SHEP1 and Sos and the crystal structure of Sos
[21], these residues lie on the opposite side of the domain from
the Ras binding site. These data begin to elucidate a picture at
the molecular level of the SHEP1–Cas complex that suggests
that the two functional roles of the GEF domain of SHEP1
are mediated by structurally distinct sites in the domain. This
may have important consequences for signaling in complex cel-
lular pathways.
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